Validity of a vasculitis activity index for systemic necrotizing vasculitis

Arthritis and Rheumatism

Volumn 42, Issue 11, 1999, Pages 2365-2371

  Whiting O'Keefe, Quinn E ^a   Stone, John H ^b   Hellmann, David B ^b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; DISEASE ACTIVITY; DISEASE MARKER; NECROTIZING ARTERITIS; PRIORITY JOURNAL; REMISSION; REPRODUCIBILITY; RHEUMATIC DISEASE;

HEALTH SURVEYS; HUMANS; PILOT PROJECTS; QUESTIONNAIRES; REPRODUCIBILITY OF RESULTS; RHEUMATOLOGY; SEVERITY OF ILLNESS INDEX; VASCULITIS;

EID: 0033499035     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/1529-0131(199911)42:11<2365::AID-ANR15>3.0.CO;2-M     Document Type: Article

References (18)

1. Petri M, Hellmann D, Hochberg MC. Validity and reliability of lupus activity measures in the routine clinic setting. J Rheumatol 1992;19:53-9.
2. Liang MH, Socher SA, Roberts WN, Esdaile JM. Measurement of systemic lupus erythematosus activity in clinical research. Arthritis Rheum 1988;31:817-25.
3. Liang MH, Socher SA, Larson MG, Schur PH. Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum 1989;32:1107-18.
4. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH, and the Committee on Prognosis Studies in SLE. Derivation of the SLEDAI: a disease activity index for lupus patients. Arthritis Rheum 1992;35:630-40.
5. Symmons DPM, Coppock JS, Bacon PA, Bresnihan B, Isenberg DA, Maddison P, et al. Development and assessment of a computerized index of clinical disease activity in systemic lupus erythematosus. QJM 1988;69:927-37.
6. Urowitz MB, Gladman DD, Tozman ECS, Goldsmith CH. The lupus activity criteria count. J Rheumatol 1984;11:783-7.
7. Hellmann DB, Petri M, Whiting-O'Keefe Q. Fatal infections in systemic lupus erythematosus: role of opportunistic organisms. Medicine (Baltimore) 1987;66:341-8.
8. Petri M, Bockenstedt L, Colman J, Whiting-O'Keefe Q, Fritz JG, Sabastian A, et al. Serial assessment of glomerular filtration rate in lupus nephropathy. Kidney Int 1988;34:832-9.
9. Ratain JS, Hochberg MC. Clinical trials: a guide to understanding methodology and interpreting results. Arthritis Rheum 1990;33: 131-9.
10. Boers M, Tugwell P. The validity of pooled outcome measures (indices) in rheumatoid arthritis clinical trials. J Rheumatol 1993; 20:568-74.
11. Kallenberg CCM, Cohen Tervaert JW, Stegeman CA. Criteria for disease activity in Wegener's granulomatosis: a requirement for longitudinal clinical studies. APMIS Suppl 1990;19:37-9.
12. Reinhold-Keller E, Kekow J, Schnabel A, Schmitt WH, Heller M, Beigel A, et al. Influence of disease manifestation and antineutrophil cytoplasmic antibody titer on the response to pulse cyclophosphamide therapy in patients with Wegener's granulomatosis. Arthritis Rheum 1994;37:919-24.
13. Luqmani RA, Bacon PA, Moots RJ, Janssen BA, Pall A, Emery P, et al. Birmingham vasculitis activity score (BVAS) in SNV. QJM 1994;87:671-8.
14. Jayne DRW, Rasmussen N. Treatment of antineutrophil cytoplasm autoantibody associated systemic vasculitis: initiatives of the European Community Systemic Vasculitis Clinical Trials Study Group. Mayo Clin Proc 1997;72:737-47.
15. Cupps T, Fauci A. Major problems in internal medicine. Vol. 21. The vasculitides. Philadelphia: WB Saunders; 1981. p. 26-49.
16. SAS Institute, Inc. SAS/STAT user's guide, version 6. Vol. 2. 4th ed. Cary (NC): SAS Institute; 1989.
17. Neter J, Kutner MH, Nachtsheim CJ, Wasserman W. Applied linear statistical models. 4th ed. Chicago: Irwin; 1996.
18. Tugwell P, Bombardier C. A methodologic framework for developing and selecting endpoints in clinical trials. J Rheumatol 1982;9:758-862.